Oregon Health & Science University
Targeting signaling and epigenetic dysfunction in CSF3R-driven leukemias
May 11, 2020
Research in my laboratory is centered on uncovering the biochemical, signaling, and epigenetic defects that drive myeloid disorders. Our long-term goal is to harness this mechanistic understanding to facilitate the development of better treatments for patients. Our group is part of the Knight Cancer Institute at Oregon Health and & Science University, located in beautiful Portland, Oregon.
Keywords
myeloid leukemia, CSF3R, epigenetic regulation, targeted therapies
Blood and Bone Seminar 